Treatment Free Remission Assessment after Discontinuation or dose Reduction of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients

Chronic myeloid leukaemia (CML) is now more than ever the model for targeted treatment in human cancers. The success of imatinib and second-generation tyrosine kinase inhibitors (TKIs) has significantly improved the prognosis of CML patients. Because TKI-treated CML patients have a near-normal life span, two key concerns must be addressed in the future: (1) the treatment's quality of life and ethical implications, and (2) the economic effect of treating patients during their lifespan. One of the most effective methods to examine these two concerns is to ask about quitting TKI in excellent responder patients. Such a technique has now been advocated in multiple studies, and hundreds of patients have formally ceased TKI in clinical trials throughout the world for molecular efficacy.

Aim of the Work: The aim of the present study is to assess:

Treatment free remission over one year in chronic phase CML patients in deep molecular response for two years or more.

Quality of life of CML patients and economic factor after treatment discontinuation or dose reduction.